New Medications for Dry Eye and Presbyopia - Summary - MDSpire
Advertisement
New Medications for Dry Eye and Presbyopia
Topical miotics are approved for use in all adults with presbyopia, including post-LASIK patients and pseudophakes, and acoltremon is a treatment option for multiple dry eye subtypes, either as primary therapy or adjunctive treatment.
By
Sarah Fackler, managing editor, Optometric Management
To review new topical prescription therapies for presbyopia and dry eye disease.
Key Findings:
Pilocarpine showed over 52% of patients achieving 20/40 DCNVA or better within 15 days (P<.0001).
Aceclidine demonstrated a rapid onset of effect with 71% of participants achieving significant near vision improvement (P<.0001).
Acoltremon met primary endpoints in phase 3 trials with significant improvements in tear production and symptom scores (P<.0001).
Interpretation:
New therapies like pilocarpine, aceclidine, and acoltremon provide effective treatment options for presbyopia and dry eye disease, with varying mechanisms and dosing regimens.
Limitations:
Adverse events reported include headache, instillation site pain, and dim vision. Caution is advised for patients with specific conditions such as iritis and other ocular pathologies.
Conclusion:
Topical miotics and neuromodulators expand treatment options for presbyopia and dry eye, with ongoing investigations into additional therapies like qASED and reproxalap.
